Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$4.65 ▲ +0.06
(+1.31%)
MKT CAP: $50.5M • VOL: 11.3K
52W L $4 52W H $6
POCI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $19.1M | $19.1M | $21.0M |
| YoY Revenue Growth % | -0.1% | -9.2% | — |
| Gross Profit | $3.4M | $5.8M | — |
| Gross Margin % | 17.8% | 30.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$5.6M | -$2.7M | -$638.5K |
| Operating Margin % | -29.1% | -14.3% | -3.0% |
| Net Income (GAAP) | -$5.8M | -$3.0M | -$144.6K |
| EBITDA (Normalized) | -$5.4M | -$2.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$3.4M | -$2.7M | -$81.1K |
| Capital Expenditures (CapEx) | $227.2K | $272.4K | — |
| Free Cash Flow (FCF) | -$3.6M | -$3.0M | -$81.1K |
| FCF Margin % | -19.0% | -15.5% | -0.4% |
| Return on Invested Capital (ROIC %) | -45.0% | -19.8% | — |
| Cash & Short-Term Equivalents | $881.5K | $212.4K | — |
| Total Debt (Short + Long Term) | $1.0M | $1.6M | — |
| Total Stockholders' Equity | $9.3M | $9.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR POCI.